Description
Pfizer’s $64 Billion Revenue Outlook: Is Wall Street Missing the Bigger Patent Cliff Risk?
Pfizer Inc. reported a third-quarter 2026 revenue of $16.7 billion, surpassing expectations with 7% operational growth from non-COVID products. The company’s launched and acquired products contributed significantly, growing operationally by 32%, driven primarily by oncology drug Padcev, migraine treatment Nurtec, and Lorbrena. This growth illustrates Pfizer’s shifting commercial momentum as COVID-19 revenues decline. Adjusted diluted earnings per share (EPS) reached $0.87, exceeding estimates despite a $0.10 charge related to the Innovent transaction. The company also raised its full-year revenue guidance to $62 billion to $64 billion and adjusted diluted EPS guidance to a range of $2.95 to $3.05. Pfizer continues to focus on operational efficiency and pipeline investment, aiming for sustained growth despite upcoming challenges. The firm is on track to achieve $7.2 billion in net cost savings by the end of 2026 with an additional $2.5 billion targeted from 2027 to 2029.



